These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12818418)

  • 21. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome.
    Romero FI; Atsumi T; Tinahones FJ; Gómez-Zumaquero JM; Amengual O; Khamashta MA; Hughes GR
    Arthritis Rheum; 1999 Dec; 42(12):2606-11. PubMed ID: 10616007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased autoantibodies against oxidized low-density lipoprotein in coronary circulation in patients with coronary spastic angina.
    Ogawa H; Soejima H; Takazoe K; Miyamoto S; Kajiwara I; Shimomura H; Sakamoto T; Yoshimura M; Kugiyama K; Kimura M; Yasue H
    Angiology; 2001 Mar; 52(3):167-74. PubMed ID: 11269779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction.
    Gruzdeva O; Uchasova E; Dyleva Y; Belik E; Karetnikova V; Shilov A; Barbarash O
    Lipids Health Dis; 2014 Jul; 13():111. PubMed ID: 25008008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
    Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
    Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction.
    Tornvall P; Karpe F; Carlson LA; Hamsten A
    Atherosclerosis; 1991 Sep; 90(1):67-80. PubMed ID: 1799399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating antibodies recognising oxidatively-modified low-density lipoproteins in patients with IgA nephropathy, membranous glomerulonephritis and focal glomerulosclerosis.
    Fornasieri A; Perugini C; Seccia M; Napodano P; D'Amico G; Bellomo G
    J Nephrol; 2002; 15(4):349-57. PubMed ID: 12243363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease.
    Soto Y; Conde H; Aroche R; Brito V; Luaces P; Nasiff A; Obregón A; Vázquez López AM
    Hum Antibodies; 2009; 18(3):109-17. PubMed ID: 19729805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive immunity is related to coronary artery disease severity after acute coronary syndrome in subjects with metabolic syndrome.
    Izar MC; Fonseca HA; Pinheiro LF; Monteiro CM; Póvoa RM; Monteiro AM; Figueiredo-Neto AM; Gidlund MA; Fonseca FA
    Diab Vasc Dis Res; 2013 Jan; 10(1):32-9. PubMed ID: 22529217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease.
    Erkkilä AT; Närvänen O; Lehto S; Uusitupa MI; Ylä-Herttuala S
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):204-9. PubMed ID: 10634819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins.
    Slot MC; Theunissen R; van Paassen P; Damoiseaux JG; Tervaert JW;
    Clin Exp Immunol; 2007 Aug; 149(2):257-64. PubMed ID: 17521320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males.
    Barud W; Palusiński R; Bełtowski J; Wójcicka G
    Atherosclerosis; 2002 Oct; 164(2):283-8. PubMed ID: 12204799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease.
    Orem A; Cimşit G; Değer O; Vanizor B; Karahan SC
    Dermatology; 1999; 198(3):243-6. PubMed ID: 10393445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia.
    Hulthe J; Wikstrand J; Lidell A; Wendelhag I; Hansson GK; Wiklund O
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1203-11. PubMed ID: 9714126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease.
    Inoue T; Uchida T; Kamishirado H; Takayanagi K; Hayashi T; Morooka S
    J Am Coll Cardiol; 2001 Mar; 37(3):775-9. PubMed ID: 11693751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Autoantibodies against oxidised low density lipoproteins in patients with coronary disease].
    Maggi E; Perani G; Falaschi F; Frattoni A; Martignoni A; Finardi G; Stefano PL; Simeone F; Paolini G; DeVecchi E
    Presse Med; 1994 Jul 2-9; 23(25):1158-62. PubMed ID: 7971845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies against oxLDL and acute coronary syndrome.
    Medeiros AM; von Mühlen CA; Gidlund MA; Bodanese R; Gottlieb MG; Bodanese LC
    Arq Bras Cardiol; 2010 Jul; 95(1):47-54. PubMed ID: 20563523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significantly higher levels of oxidized LDL autoantibody in coronary artery disease patients.
    Liang KW; Huang JL; Kao CH; Hsueh CW; Ho HY; Lee WL; Wang KY; Huang DS; Chen YT; Ting CT
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):101-6. PubMed ID: 10677919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoantibody against oxidised LDL and progression of carotid atherosclerosis.
    Salonen JT; Ylä-Herttuala S; Yamamoto R; Butler S; Korpela H; Salonen R; Nyyssönen K; Palinski W; Witztum JL
    Lancet; 1992 Apr; 339(8798):883-7. PubMed ID: 1348295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
    Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
    Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.